| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.586 | 0.008 | 0.72 | Anticonvulsant | 0.72 0.005 CID_166774 | CID_166774 | |
| 0.538 | 0.002 | 0.593 | Benzodiazepine agonist | 0.593 0.002 CID_166774 | CID_166774 | |
| 0.525 | 0.023 | 0.525 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.45 0.061 CID_166774 | ||
| 0.499 | 0.004 | 0.499 | Glutamate receptor antagonist | 0.208 0.023 CID_166774 | ||
| 0.513 | 0.023 | 0.513 | GABA C receptor rho-3 antagonist | 0.255 0.15 CID_166774 | ||
| 0.485 | 0.003 | 0.536 | GABA receptor antagonist | 0.536 0.003 CID_166774 | CID_166774 | |
| 0.447 | 0.004 | 0.495 | GABA A receptor antagonist | 0.495 0.003 CID_166774 | CID_166774 | |
| 0.439 | 0.011 | 0.439 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.348 0.024 CID_166774 | ||
| 0.418 | 0.034 | 0.418 | Aryl hydrocarbon receptor agonist | 0.31 0.058 CID_166774 | ||
| 0.374 | 0.005 | 0.531 | GABA receptor agonist | 0.531 0.004 CID_166774 | CID_166774 | |
| 0.362 | 0.005 | 0.362 | Glutamate (mGluR) antagonist | |||
| 0.367 | 0.022 | 0.367 | RNA-directed DNA polymerase inhibitor | 0.327 0.027 CID_166774 | ||
| 0.337 | 0.004 | 0.337 | Glutamate (mGluR group I) antagonist | |||
| 0.39 | 0.065 | 0.39 | MAP kinase kinase 6 inhibitor | 0.326 0.112 CID_166774 | ||
| 0.355 | 0.034 | 0.469 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.469 0.01 CID_166774 | CID_166774 | |
| 0.346 | 0.026 | 0.346 | Platelet aggregation inhibitor | |||
| 0.317 | 0.014 | 0.317 | Glycogen synthase kinase-3 alpha inhibitor | 0.133 0.077 CID_166774 | ||
| 0.331 | 0.034 | 0.331 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.211 0.07 CID_166774 | ||
| 0.335 | 0.039 | 0.335 | Pyruvate kinase inhibitor | 0.327 0.041 CID_166774 | ||
| 0.402 | 0.11 | 0.465 | Caspase 9 stimulant | 0.465 0.075 CID_166774 | CID_166774 | |
| 0.326 | 0.042 | 0.326 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.175 0.109 CID_166774 | ||
| 0.318 | 0.046 | 0.318 | Dyrk kinase inhibitor | 0.166 0.121 CID_166774 | ||
| 0.298 | 0.036 | 0.298 | MAP kinase kinase 2 inhibitor | 0.209 0.076 CID_166774 | ||
| 0.319 | 0.074 | 0.319 | Calcium channel activator | |||
| 0.262 | 0.022 | 0.262 | MAP kinase kinase 3 inhibitor | 0.248 0.034 CID_166774 | ||
| 0.245 | 0.008 | 0.245 | Polo-like kinase-4 inhibitor | 0.131 0.048 CID_166774 | ||
| 0.275 | 0.041 | 0.275 | ErbB-1 antagonist | 0.216 0.073 CID_166774 | ||
| 0.276 | 0.042 | 0.282 | Peroxidase inhibitor | 0.282 0.041 CID_166774 | CID_166774 | |
| 0.276 | 0.052 | 0.276 | Cyclic AMP phosphodiesterase inhibitor | |||
| 0.269 | 0.045 | 0.269 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.243 0.075 CID_166774 | ||
| 0.24 | 0.018 | 0.24 | Cyclin-dependent kinase 3 inhibitor | 0.223 0.023 CID_166774 | ||
| 0.221 | 0.003 | 0.221 | Purinergic P2X4 antagonist | 0.058 0.016 CID_166774 | ||
| 0.226 | 0.008 | 0.247 | Interleukin 8 antagonist | 0.247 0.006 CID_166774 | CID_166774 | |
| 0.281 | 0.065 | 0.305 | DNA damaging | 0.305 0.055 CID_166774 | CID_166774 | |
| 0.248 | 0.034 | 0.248 | Nitric-oxide synthase stimulant | 0.218 0.063 CID_166774 | ||
| 0.212 | 0.004 | 0.212 | Glutamate (mGluR1) antagonist | |||
| 0.209 | 0.004 | 0.209 | AMPA receptor antagonist | 0.167 0.005 CID_166774 | ||
| 0.244 | 0.041 | 0.244 | LIM domain kinase 1 inhibitor | 0.129 0.122 CID_166774 | ||
| 0.222 | 0.021 | 0.222 | Platelet activating factor antagonist | |||
| 0.203 | 0.004 | 0.203 | Glutamate (mGluR5) antagonist | |||
| 0.286 | 0.088 | 0.286 | 12-Lipoxygenase inhibitor | |||
| 0.244 | 0.047 | 0.367 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.367 0.023 CID_166774 | CID_166774 | |
| 0.328 | 0.134 | 0.328 | Calcium channel L-type activator | |||
| 0.211 | 0.023 | 0.211 | GABA C receptor rho-2 antagonist | 0.129 0.107 CID_166774 | ||
| 0.256 | 0.068 | 0.256 | 5 Hydroxytryptamine 1E antagonist | |||
| 0.184 | 0.004 | 0.184 | GABA B receptor antagonist | 0.063 0.011 CID_166774 | ||
| 0.209 | 0.029 | 0.209 | Death-associated protein kinase 2 inhibitor | 0.207 0.03 CID_166774 | ||
| 0.199 | 0.023 | 0.199 | MAP kinase 12 inhibitor | 0.177 0.03 CID_166774 | ||
| 0.183 | 0.012 | 0.183 | GABA A receptor agonist | |||
| 0.222 | 0.054 | 0.222 | I kappa B kinase epsilon inhibitor | 0.149 0.12 CID_166774 | ||
| 0.172 | 0.005 | 0.172 | Phosphodiesterase II inhibitor | |||
| 0.225 | 0.062 | 0.453 | Anesthetic general | 0.453 0.011 CID_166774 | CID_166774 | |
| 0.161 | 0.005 | 0.161 | Phosphodiesterase 2A inhibitor | |||
| 0.167 | 0.014 | 0.167 | Pim-3 kinase inhibitor | 0.118 0.032 CID_166774 | ||
| 0.213 | 0.06 | 0.213 | Focal adhesion kinase 2 inhibitor | |||
| 0.182 | 0.031 | 0.182 | DNA intercalator | 0.132 0.051 CID_166774 | ||
| 0.167 | 0.019 | 0.167 | DNA directed RNA polymerase inhibitor | |||
| 0.163 | 0.016 | 0.288 | Potassium channel activator | 0.288 0.004 CID_166774 | CID_166774 | |
| 0.199 | 0.052 | 0.199 | 3C-like protease (Human coronavirus) inhibitor | |||
| 0.155 | 0.009 | 0.155 | CDC7 inhibitor | 0.079 0.036 CID_166774 | ||
| 0.21 | 0.069 | 0.21 | Death-associated protein kinase 3 inhibitor | 0.16 0.107 CID_166774 | ||
| 0.169 | 0.028 | 0.169 | MAP kinase 13 inhibitor | 0.15 0.036 CID_166774 | ||
| 0.177 | 0.037 | 0.177 | Glycogen synthase kinase-3 inhibitor | |||
| 0.185 | 0.054 | 0.185 | Polo-like kinase-3 inhibitor | |||
| 0.148 | 0.017 | 0.148 | CYP2A6 inhibitor | |||
| 0.157 | 0.027 | 0.157 | GABA C receptor antagonist | |||
| 0.141 | 0.015 | 0.184 | Cyclin B3 inhibitor | 0.184 0.008 CID_166774 | CID_166774 | |
| 0.168 | 0.042 | 0.168 | MAP kinase kinase inhibitor | |||
| 0.163 | 0.038 | 0.163 | Glycogen synthase kinase-3 beta inhibitor | |||
| 0.298 | 0.174 | 0.298 | Apoptosis agonist | |||
| 0.202 | 0.078 | 0.202 | Clk dual-specificity kinase inhibitor | |||
| 0.157 | 0.037 | 0.157 | Cyclin-dependent kinase 5 inhibitor | 0.149 0.041 CID_166774 | ||
| 0.174 | 0.057 | 0.174 | Cyclin-dependent kinase 8 inhibitor | |||
| 0.157 | 0.042 | 0.157 | Aurora-C kinase inhibitor | 0.139 0.066 CID_166774 | ||
| 0.207 | 0.095 | 0.261 | MAP-kinase-activated kinase 5 inhibitor | 0.261 0.053 CID_166774 | CID_166774 | |
| 0.142 | 0.032 | 0.142 | Falcipain 2 inhibitor | |||
| 0.144 | 0.034 | 0.144 | Falcipain inhibitor | |||
| 0.167 | 0.057 | 0.167 | CDC-like kinase 1 inhibitor | 0.115 0.101 CID_166774 | ||
| 0.137 | 0.029 | 0.137 | NMDA receptor antagonist | 0.087 0.057 CID_166774 | ||
| 0.161 | 0.06 | 0.161 | Thiol protease inhibitor | |||
| 0.194 | 0.095 | 0.194 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.152 0.142 CID_166774 | ||
| 0.158 | 0.058 | 0.158 | Mannose-6-phosphate isomerase inhibitor | 0.133 0.082 CID_166774 | ||
| 0.223 | 0.126 | 0.223 | Insulysin inhibitor | |||
| 0.182 | 0.091 | 0.182 | Psychostimulant | 0.178 0.094 CID_166774 | ||
| 0.133 | 0.042 | 0.133 | EphA2 antagonist | |||
| 0.102 | 0.013 | 0.102 | Phospholipase D inhibitor | 0.07 0.054 CID_166774 | ||
| 0.172 | 0.084 | 0.172 | TRKC antagonist | |||
| 0.124 | 0.037 | 0.124 | GABA C receptor rho-1 antagonist | |||
| 0.125 | 0.04 | 0.125 | Urease inhibitor | 0.111 0.055 CID_166774 | ||
| 0.151 | 0.066 | 0.173 | MAP kinase 3 inhibitor | 0.173 0.04 CID_166774 | CID_166774 | |
| 0.145 | 0.061 | 0.145 | Phosphodiesterase inhibitor | |||
| 0.091 | 0.008 | 0.091 | CDK5/p25 inhibitor | 0.049 0.022 CID_166774 | ||
| 0.144 | 0.061 | 0.144 | Heat shock protein 70 antagonist | 0.143 0.066 CID_166774 | ||
| 0.209 | 0.127 | 0.209 | Streptokinase A inhibitor | |||
| 0.124 | 0.042 | 0.177 | Beta glucuronidase inhibitor | 0.177 0.016 CID_166774 | CID_166774 | |
| 0.126 | 0.045 | 0.126 | Protein kinase (CK2) inhibitor | |||
| 0.127 | 0.047 | 0.175 | Protein kinase C gamma inhibitor | 0.175 0.02 CID_166774 | CID_166774 | |
| 0.132 | 0.054 | 0.132 | Protein kinase (CK2) alpha inhibitor | |||
| 0.095 | 0.016 | 0.095 | Pim-2 kinase inhibitor | 0.058 0.033 CID_166774 | ||
| 0.148 | 0.07 | 0.148 | Protein kinase (CK1) gamma 1 inhibitor | |||
| 0.174 | 0.096 | 0.174 | Growth factor agonist | |||
| 0.165 | 0.089 | 0.165 | CDC-like kinase 4 inhibitor | |||
| 0.108 | 0.032 | 0.108 | Porphobilinogen synthase inhibitor | 0.102 0.035 CID_166774 | ||
| 0.08 | 0.005 | 0.08 | Benzodiazepine antagonist | 0.066 0.009 CID_166774 | ||
| 0.184 | 0.11 | 0.184 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | |||
| 0.131 | 0.058 | 0.131 | Protein kinase (CK1) gamma 2 inhibitor | |||
| 0.122 | 0.05 | 0.122 | Activin receptor-like kinase 4 inhibitor | 0.098 0.091 CID_166774 | ||
| 0.154 | 0.083 | 0.154 | Sigma receptor agonist | |||
| 0.142 | 0.072 | 0.142 | Protein kinase (CK1) gamma inhibitor | |||
| 0.153 | 0.084 | 0.153 | Heat shock protein 90 alpha antagonist | |||
| 0.103 | 0.036 | 0.103 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.093 0.045 CID_166774 | ||
| 0.083 | 0.016 | 0.083 | MDM2 inhibitor | |||
| 0.112 | 0.048 | 0.112 | Fibroblast growth factor 1 antagonist | |||
| 0.138 | 0.076 | 0.287 | Protein kinase C nu inhibitor | 0.287 0.027 CID_166774 | CID_166774 | |
| 0.137 | 0.077 | 0.137 | Vascular endothelial growth factor 3 antagonist | |||
| 0.107 | 0.048 | 0.107 | MAP kinase kinase 1 inhibitor | |||
| 0.137 | 0.078 | 0.137 | Activin receptor-like kinase 2 inhibitor | |||
| 0.132 | 0.073 | 0.132 | Proto-oncogene tyrosine-protein kinase Yes inhibitor | |||
| 0.067 | 0.011 | 0.067 | Benzodiazepine inverse agonist | 0.046 0.034 CID_166774 | ||
| 0.098 | 0.043 | 0.098 | Leucine-rich repeat kinase 2 inhibitor | |||
| 0.067 | 0.013 | 0.111 | Kainate receptor antagonist | 0.111 0.006 CID_166774 | CID_166774 | |
| 0.062 | 0.008 | 0.062 | Histamine H1 receptor agonist | |||
| 0.092 | 0.038 | 0.092 | Nicotinic alpha4beta2 receptor antagonist | |||
| 0.131 | 0.078 | 0.131 | Death-associated protein kinase 1 inhibitor | 0.124 0.1 CID_166774 | ||
| 0.073 | 0.02 | 0.073 | Nicotinic receptor alpha7 subunit antagonist | |||
| 0.072 | 0.02 | 0.086 | Cyclin B2 inhibitor | 0.086 0.012 CID_166774 | CID_166774 | |
| 0.076 | 0.025 | 0.088 | Cyclin B1 inhibitor | 0.088 0.016 CID_166774 | CID_166774 | |
| 0.095 | 0.044 | 0.095 | MAP-kinase-activated kinase inhibitor | 0.077 0.066 CID_166774 | ||
| 0.062 | 0.011 | 0.062 | Kainate receptor 2 antagonist | 0.037 0.024 CID_166774 | ||
| 0.091 | 0.041 | 0.091 | MAP kinase 11 inhibitor | |||
| 0.109 | 0.06 | 0.109 | Cyclin-dependent kinase 2 inhibitor | |||
| 0.13 | 0.083 | 0.13 | Protein kinase (CK1) inhibitor | |||
| 0.083 | 0.037 | 0.083 | Prostaglandin-E synthase inhibitor | |||
| 0.084 | 0.04 | 0.084 | MAP-kinase-activated kinase 2 inhibitor | 0.069 0.059 CID_166774 | ||
| 0.09 | 0.046 | 0.09 | Acetylcholine nicotinic agonist | |||
| 0.095 | 0.051 | 0.095 | Histamine N-methyltransferase inhibitor | |||
| 0.067 | 0.024 | 0.082 | Cyclin B inhibitor | 0.082 0.015 CID_166774 | CID_166774 | |
| 0.118 | 0.075 | 0.118 | Cyclin-dependent kinase inhibitor | |||
| 0.107 | 0.065 | 0.107 | Topoisomerase I inhibitor | 0.085 0.084 CID_166774 | ||
| 0.088 | 0.047 | 0.088 | Acetylcholine nicotinic antagonist | |||
| 0.095 | 0.053 | 0.095 | Polo-like kinase-1 inhibitor | |||
| 0.052 | 0.011 | 0.052 | AMPA 1 receptor antagonist | 0.035 0.017 CID_166774 | ||
| 0.078 | 0.038 | 0.078 | Neuronal nicotinic receptor antagonist | |||
| 0.155 | 0.115 | 0.155 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | |||
| 0.093 | 0.053 | 0.093 | Antineoplastic alkaloid | 0.09 0.055 CID_166774 | ||
| 0.103 | 0.064 | 0.103 | Vascular endothelial growth factor 1 antagonist | |||
| 0.047 | 0.009 | 0.177 | Benzodiazepine receptor peripheral-type antagonist | 0.177 0.003 CID_166774 | CID_166774 | |
| 0.101 | 0.065 | 0.101 | Cyclin-dependent kinase 1 inhibitor | 0.1 0.066 CID_166774 | ||
| 0.105 | 0.069 | 0.105 | Nav1.4 sodium channel blocker | |||
| 0.065 | 0.03 | 0.065 | Cyclin A1 inhibitor | |||
| 0.157 | 0.122 | 0.157 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | |||
| 0.065 | 0.03 | 0.082 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.082 0.019 CID_166774 | CID_166774 | |
| 0.078 | 0.045 | 0.085 | Protein kinase B beta inhibitor | 0.085 0.037 CID_166774 | CID_166774 | |
| 0.098 | 0.066 | 0.098 | MAO A inhibitor | |||
| 0.095 | 0.063 | 0.095 | Pim-1 kinase inhibitor | |||
| 0.083 | 0.051 | 0.083 | Phosphodiesterase 3A inhibitor | |||
| 0.044 | 0.012 | 0.044 | AMPA 3 receptor antagonist | 0.03 0.02 CID_166774 | ||
| 0.059 | 0.027 | 0.059 | Nicotinic alpha3beta2 receptor antagonist | |||
| 0.118 | 0.086 | 0.157 | Ca2+/calmodulin-dependent kinase II delta inhibitor | 0.157 0.061 CID_166774 | CID_166774 | |
| 0.092 | 0.061 | 0.126 | Protein kinase C zeta inhibitor | 0.126 0.029 CID_166774 | CID_166774 | |
| 0.051 | 0.02 | 0.051 | Glutamate (mGluR4) antagonist | |||
| 0.121 | 0.09 | 0.121 | Growth factor antagonist | |||
| 0.084 | 0.053 | 0.084 | Platelet growth factor antagonist | |||
| 0.102 | 0.073 | 0.102 | 5 Hydroxytryptamine 3A agonist | |||
| 0.052 | 0.023 | 0.052 | Phosphodiesterase 3B inhibitor | |||
| 0.109 | 0.08 | 0.109 | Histone deacetylase class III inhibitor | |||
| 0.071 | 0.043 | 0.071 | Phosphodiesterase III inhibitor | |||
| 0.12 | 0.091 | 0.12 | Histone deacetylase SIRT1 inhibitor | |||
| 0.079 | 0.052 | 0.079 | NAD(P)H dehydrogenase (quinone) inhibitor | |||
| 0.051 | 0.024 | 0.051 | NMDA receptor subunit 3B antagonist | |||
| 0.133 | 0.106 | 0.133 | CDC-like kinase 2 inhibitor | |||
| 0.069 | 0.044 | 0.069 | Glutamate (mGluR7) antagonist | |||
| 0.035 | 0.01 | 0.035 | NMDA receptor glycine site antagonist | 0.022 0.019 CID_166774 | ||
| 0.071 | 0.045 | 0.071 | Phenylalanine 4-hydroxylase inhibitor | 0.063 0.054 CID_166774 | ||
| 0.116 | 0.094 | 0.116 | Interleukin 1 antagonist | |||
| 0.053 | 0.031 | 0.053 | Adenosine A2b receptor antagonist | |||
| 0.037 | 0.015 | 0.037 | Protein kinase (CK2) beta inhibitor | 0.032 0.027 CID_166774 | ||
| 0.043 | 0.021 | 0.043 | Protein kinase (CK1) epsilon inhibitor | |||
| 0.033 | 0.012 | 0.033 | Kainate receptor 4 antagonist | 0.028 0.015 CID_166774 | ||
| 0.046 | 0.025 | 0.046 | Glutamate (mGluR group III) antagonist | |||
| 0.036 | 0.017 | 0.036 | Methionyl aminopeptidase 1 inhibitor | |||
| 0.102 | 0.083 | 0.102 | Acetylcholine release stimulant | |||
| 0.062 | 0.044 | 0.062 | Prostaglandin F2 alpha antagonist | 0.056 0.054 CID_166774 | ||
| 0.1 | 0.082 | 0.1 | Aurora-B kinase inhibitor | |||
| 0.122 | 0.104 | 0.122 | Dual specificity tyrosine-phosphorylation regulated kinase 1B inhibitor | |||
| 0.056 | 0.039 | 0.056 | Nicotinic neuronal receptor agonist | |||
| 0.119 | 0.102 | 0.162 | Cytidine deaminase inhibitor | 0.162 0.067 CID_166774 | CID_166774 | |
| 0.028 | 0.011 | 0.028 | Kainate receptor 1 antagonist | |||
| 0.041 | 0.024 | 0.041 | NMDA receptor subunit 3A antagonist | |||
| 0.033 | 0.017 | 0.033 | Nicotinic alpha3beta4 receptor agonist | |||
| 0.105 | 0.09 | 0.105 | Epidermal growth factor receptor kinase inhibitor | |||
| 0.04 | 0.026 | 0.04 | AMPA 4 receptor antagonist | |||
| 0.053 | 0.039 | 0.053 | Nicotinic alpha7 receptor agonist | |||
| 0.076 | 0.063 | 0.076 | Glycine receptor antagonist | |||
| 0.107 | 0.094 | 0.107 | Cathepsin H inhibitor | |||
| 0.069 | 0.056 | 0.069 | Histone deacetylase SIRT2 inhibitor | |||
| 0.08 | 0.067 | 0.08 | Insulin growth factor antagonist | |||
| 0.077 | 0.065 | 0.077 | Insulin like growth factor 1 antagonist | |||
| 0.044 | 0.032 | 0.044 | Potassium channel small-conductance Ca-activated blocker | |||
| 0.057 | 0.047 | 0.057 | Potassium channel (Ca-activated) blocker | |||
| 0.122 | 0.111 | 0.122 | MAP3K9 inhibitor | |||
| 0.049 | 0.039 | 0.049 | Antiviral (Hepatitis D) | |||
| 0.029 | 0.021 | 0.029 | AMPA 2 receptor antagonist | |||
| 0.075 | 0.066 | 0.075 | MAP kinase 7 inhibitor | |||
| 0.086 | 0.079 | 0.086 | MAP kinase 8 inhibitor | |||
| 0.058 | 0.051 | 0.058 | Corticotropin releasing factor 2 receptor antagonist | |||
| 0.056 | 0.05 | 0.056 | Cyclin D1 inhibitor | |||
| 0.122 | 0.116 | 0.122 | Hexokinase inhibitor | |||
| 0.018 | 0.013 | 0.018 | Granulocyte colony stimulating factor receptor agonist | |||
| 0.086 | 0.081 | 0.086 | MAP kinase kinase kinase inhibitor | |||
| 0.041 | 0.036 | 0.041 | Heme oxygenase inhibitor | |||
| 0.181 | 0.177 | 0.181 | Gastrin inhibitor | |||
| 0.016 | 0.013 | 0.016 | Kainate receptor 3 antagonist | |||
| 0.019 | 0.016 | 0.019 | Kainate receptor 5 antagonist | |||
| 0.081 | 0.078 | 0.081 | Platelet activating factor beta antagonist | |||
| 0.083 | 0.081 | 0.088 | Check point kinase 2 inhibitor | 0.088 0.076 CID_166774 | CID_166774 | |
| 0.147 | 0.145 | 0.147 | Histone acetyltransferase inhibitor | |||
| 0.046 | 0.044 | 0.046 | Potassium channel (Inward rectifier) activator | |||
| 0.025 | 0.023 | 0.025 | Toll-Like receptor 4 agonist | |||
| 0.044 | 0.042 | 0.044 | Potassium channel (ATP-sensitive) activator | |||
| 0.093 | 0.092 | 0.093 | 5 Hydroxytryptamine 2B antagonist | |||
| 0.099 | 0.1 | 0.106 | Aldehyde dehydrogenase inhibitor | 0.106 0.089 CID_166774 | CID_166774 | |
| 0.069 | 0.074 | 0.089 | Protein kinase A inhibitor | 0.089 0.053 CID_166774 | CID_166774 | |
| 0.077 | 0.085 | 0.085 | Aminoacyl-tRNA synthetase inhibitor | 0.085 0.067 CID_166774 | CID_166774 | |
| 0.074 | 0.091 | 0.152 | Protein kinase C mu inhibitor | 0.152 0.025 CID_166774 | CID_166774 | |
| 0.02 | 0.049 | 0.037 | Cholecystokinin antagonist | 0.037 0.031 CID_166774 | CID_166774 | |
| 0.141 | 0.174 | 0.152 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.152 0.144 CID_166774 | CID_166774 | |
| 0.176 | 0.211 | 0.195 | Caspase 3 stimulant | 0.195 0.177 CID_166774 | CID_166774 | |
| 0.045 | 0.101 | 0.063 | Protein kinase C beta inhibitor | 0.063 0.062 CID_166774 | CID_166774 | |
| 0.02 | 0.084 | 0.033 | RNA-directed RNA polymerase inhibitor | 0.033 0.026 CID_166774 | CID_166774 | |
| 0.025 | 0.095 | 0.072 | Plasminogen activator inhibitor | 0.072 0.03 CID_166774 | CID_166774 | |
| 0.004 | 0.423 | 0.036 | 1,3-Beta-glucan synthase inhibitor | 0.036 0.005 CID_166774 | CID_166774 | |
| 0.016 | 0.67 | 0.163 | Antioxidant | 0.163 0.15 CID_166774 | CID_166774 | |
| 0.008 | 0.718 | 0.16 | Lipid peroxidase inhibitor | 0.16 0.062 CID_166774 | CID_166774 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |